Olanzapine and the new generation of antipsychotic agents: patterns of use.
As the new generation of atypical antipsychotics becomes available, the limitations of the older typical agents become apparent. The new medications, which have benefits other than the alleviation of positive symptoms of schizophrenia, may also be beneficial for psychotic disorders that have responded poorly to conventional neuroleptics. This article will describe the potential use of the atypical antipsychotics, especially olanzapine, for affective mood disturbances in schizophrenia, psychotic depression and mania, first-break schizophrenia, comorbid schizophrenia and substance abuse disorders, dementia in the elderly and those with late-onset schizophrenia, and behavioral problems in patients with mental retardation or developmental delays.
Glazer
W M
WM
Harvard Medical School, Massachusetts General Hospital, Boston, USA.
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D002648:Child; D015897:Comorbidity; D003704:Dementia / Q000188:drug therapy; D003866:Depressive Disorder / Q000188:drug therapy; D002658:Developmental Disabilities / Q000523:psychology; D017831:Diagnosis, Dual (Psychiatry); D006801:Humans; D008607:Intellectual Disability / Q000523:psychology; D001523:Mental Disorders / Q000188:drug therapy; D000077152:Olanzapine; D010890:Pirenzepine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy / Q000453:epidemiology; D019966:Substance-Related Disorders / Q000188:drug therapy / Q000453:epidemiology
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine